

(51) International Patent Classification:
A61P 35/00 (2006.01) *C07K 16/28* (2006.01)(21) International Application Number:
PCT/US2021/030466(22) International Filing Date:
03 May 2021 (03.05.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/018,952 01 May 2020 (01.05.2020) US(71) Applicant: **BOLT BIOTHERAPEUTICS, INC.**
[US/US]; 900 Chesapeake Drive, Redwood City, California
94063 (US).(72) Inventors: **ACKERMAN, Shelley Erin**; c/o Bolt Biotherapeutics, Inc., 900 Chesapeake Drive, Redwood City, California 94063 (US). **DORNAN, David**; c/o Bolt Biotherapeutics, Inc., 900 Chesapeake Drive, Redwood City, California 94063 (US). **HENNING, Karla A.**; c/o Bolt Biotherapeutics, Inc., 900 Chesapeake Drive, Redwood City, California 94063 (US). **KENKEL, Justin A.**; c/o Bolt Biotherapeutics, Inc., 900 Chesapeake Drive, Redwood City, California 94063 (US).(74) Agent: **SCHUBERT, Michael J.**; Leydig, Voit & Mayer, Ltd., Two Prudential Plaza—Suite 4900, 180 North Stetson Avenue, Chicago, Illinois 60601-6731 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ANTI-DECTIN-2 ANTIBODIES




FIG.1

(57) Abstract: The invention relates to dendritic cell-associated C-type lectin 2 (Dectin-2) binding agents, nucleic acids comprising the inventive binding agents, vectors and cells comprising the inventive nucleic acids, and compositions thereof. The invention also relates to methods of providing the inventive binding agents, methods for treating a disease, disorder, or condition in a mammal, and methods of stimulating an antigen presenting cell.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*